Currently, there are 109.08M common shares owned by the public and among those 103.39M shares have been available to trade.
The company’s stock has a 5-day price change of 6.77% and -4.72% over the past three months. TXG shares are trading -29.74% year to date (YTD), with the 12-month market performance down to -54.53% lower. It has a 12-month low price of $6.78 and touched a high of $24.76 over the same period. TXG has an average intraday trading volume of 3.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.44%, 17.60%, and -28.09% respectively.
Institutional ownership of 10x Genomics Inc (NASDAQ: TXG) shares accounts for 90.02% of the company’s 109.08M shares outstanding.
It has a market capitalization of $1.26B and a beta (3y monthly) value of 1.98. The earnings-per-share (ttm) stands at -$1.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.86% over the week and 4.44% over the month.
Earnings per share for the fiscal year are expected to increase by 20.48%, and 22.05% over the next financial year. EPS should grow at an annualized rate of 25.49% over the next five years, compared to -36.10% over the past 5-year period.
Looking at the support for the TXG, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on February 13, 2025, with the firm’s price target at $25-$12. Leerink Partners coverage for the 10x Genomics Inc (TXG) stock in a research note released on September 03, 2024 offered a Outperform rating with a price target of $35. Jefferies was of a view on July 22, 2024 that the stock is Buy, while JP Morgan gave the stock Neutral rating on July 18, 2024, issuing a price target of $40- $20. Deutsche Bank on their part issued Hold rating on July 10, 2024.
